Cinven sale shows bubble deals can turn a profit

Cinven's 3.5x exit on diagnostics group Phadia, purchased at the peak of the market in a secondary buyout, represents its second €1bn-plus gain this year.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this